- Gene-based AAVCOVID vaccine employs a unique adeno-associated viral vector (AAV) technology that was shown in non-clinical, nonhuman primate studies to enable protection from SARS-CoV-2 challenge and to induce sustained antibody and cellular immune responses from a single dose for up to a year
- Production of the vaccine was able to leverage commercial-scale processes established by Novartis Gene Therapies
- Storage stability at room temperature for up to one month raises possibility for distribution without refrigeration
- Researchers hope evidence can lead to clinical trials with goal of global distribution, given single-dose and room temperature-stable properties
An international collaboration led by Luk H. Vandenberghe, PhD, in the Department of Ophthalmology at Mass Eye and Ear, a member of Mass General Brigham, reported that a novel, gene-based COVID-19 vaccine leveraging a unique adeno-associated viral vector (AAV) platform was highly effective at eliciting neutralizing antibody responses and cellular immunity from a single dose. The vaccine provided nonhuman primates near-complete protection against a live SARS-CoV-2 viral challenge led by immunology researcher, Roger Le Grand, PhD, of the French Alternative Energies and Atomic Energy Commission (CEA).
With support from Novartis Gene Therapies, the AAVCOVID vaccine was shown to be producible with efficient, scalable, and industry-established manufacturing processes. The investigators further demonstrated that the vaccine product is stable at room-temperature storage conditions for up to one month, facilitating potential future distribution of the vaccine.
The new research, published September 8 in Cell Host & Microbe, represents the first peer-reviewed study to demonstrate AAVCOVID vaccine’s preclinical effectiveness and the maintenance of immunity at peak levels for at least 11 months from a single-dose immunization. The study authors hope these findings support a move towards clinical trials with a goal of global distribution in parts of the world that are currently underserved by vaccination.
“Our findings, bolstered by long-term durability and protection data, show the AAV vaccine platform may address some of the ongoing elements of the health crisis and should warrant further study in clinical trials,” said AAVCOVID principal investigator Luk H. Vandenberghe, PhD, director of the Grousbeck Gene Therapy Center at Mass Eye and Ear and Associate Professor of Ophthalmology at Harvard Medical School. “More durable and accessible vaccine options are of paramount need as the pandemic persists globally. We further believe our data validate this novel platform for consideration of other health threats for which vaccines are pursued.”
Durable immune response and vaccine potency observed
In the new study, two AAVCOVID vaccine candidates with different SARS-CoV2 virus spike-based antigens were analyzed in a battery of experiments to measure effectiveness, duration of response, potency and stability. The candidates were derived from genetic data collected on the Wuhan strain of the SARS-CoV-2 virus. One vaccine candidate, AC1, was found to be superior in its ability to produce sustained immune responses in mouse and nonhuman primate models.
Early studies in mice revealed a single injection of the AC1 AAVCOVID candidate induced significant neutralizing antibody and T-cell levels, with antibody levels persisting for more than six months.
Next, to gain a better sense of how the vaccine might work in people, the AC1 AAVCOVID candidate was studied in a nonhuman primate model. The AC1 vaccine led to antibody levels that peaked at week 11 and remained at peak for at least 11 months. The antibodies were detected in lung tissues, which may suggest mitigating some of the pulmonary effects of COVID-19 infection. The vaccine also induced long-term functional memory T-cell responses.
No adverse effects were observed in either animal model.
Further testing established the feasibility of large-scale manufacturing of the vaccine in already available industry processes through Novartis Gene Therapies. The researchers also tested cold-chain storage requirements, or the need to keep the vaccines at specific low temperatures to retain potency. They analyzed the vaccine’s potencies when stored at -112⁰F (-80⁰C), 39⁰F (4⁰C) or 77⁰F (25⁰C) to approximate freezing, refrigerated and room temperatures, respectively. The vaccine was shown to be stable after one month at room temperature, with stability at colder temperatures exceeding three months.
Immune protection supported by challenge study
Led by Dr. Le Grand, SARS-CoV-2 viral challenge studies were conducted with the AC1 vaccine candidate in nonhuman primates at the Infectious Disease Models and Innovative Therapies (IDMIT) department at CEA in Fontenay-aux-Roses, France. Compared to unvaccinated animals that showed COVID-19 infection in the nose, trachea and lung, the animals that received an AC1 immunization nine weeks prior to the challenge all demonstrated near-complete protection against COVID-19 infection. In particular, the upper airways were highly protected from COVID-19, as no major lung damage was seen in immunized animals, while two controls showed lesions caused by the virus.
“The remarkable efficacy induced in the nonhuman primate model after a single injection of the AAVCOVID vaccine does represent an important step in the development of a COVID-19 vaccine. Many possibilities are offered by the platform for antigen engineering. Rapid production scalability and easy distribution make AAV vaccines of particular interest for new pathogen threats readiness,” explained Roger Le Grand, PhD, executive director of IDMIT.
The different variants of COVID-19, including the Delta variant, were also neutralized by serum from the AC1 candidate in vaccinated animals. Consistent to other Wuhan-based vaccines currently in market, variants are neutralized to a lesser amount as compared to the ancestral strain.
AAV-based platform may address persisting global challenges in pandemic response
AAVCOVID is a vaccine strategy that employs an AAV vector – a well-studied class of viral vectors used in approved gene therapies – to deliver genetic sequences for antigens of the SARS-CoV-2 virus spike protein to elicit a sustained immune response. The vaccine employs a specific AAV designed by Dr. Vandenberghe called rh32.33, which offers favorable inflammatory properties needed for vaccines and lacks pre-existing immunity in humans. This vaccine is the first COVID-19 vaccine developed on the AAV technology. While other viral vector vaccines exist, it is highly distinct from adenoviral vaccines, several of which are currently approved worldwide for COVID-19.
“It is exciting to see the progress in developing this AAV vaccine platform against SARS Co-V-2, and the potential it holds for future vaccine development against other pathogens,” said Joan W. Miller, MD, Chief of Ophthalmology at Mass Eye and Ear, Mass General Hospital, and Brigham and Women’s Hospital, and Chair of Ophthalmology and David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School. “This is a wonderful example of successful international collaborative research, which is especially critical when addressing a global pandemic like COVID-19.”
The new study showed that an AAVCOVID vaccine can address some of the biological and logistical hurdles that have persisted since the pandemic began, and more than six months since vaccines became approved for use.
There remains a critical need for additional vaccination strategies, as rollouts of approved vaccines have been uneven worldwide, especially in low- and middle-income countries. Most COVID-19 vaccines require two injections, and the need for a booster may become a reality, as the duration of effectiveness has been reported to wane over time. A single-dose vaccine that offers one-year-immunity can not only offer a solution that is more desirable for adherence, but also decrease billions of dollars in global healthcare costs associated with the production of multiple-dose and booster vaccines.
An AAV-based vaccine can also leverage existing manufacturing facilities used to produce and distribute AAV-based gene therapies.
Cold storage also remains a challenge in many parts of the world, and AAVCOVID’s ability to retain potency and stability for up to one month at room temperature could address some of these challenges.
“We believe an AAVCOVID vaccine has the potential to provide a more accessible option for people across the globe, especially to those with limited access to medical care, “ said first study author Nerea Zabaleta Lasarte, PhD, a postdoctoral research fellow at the Grousbeck Gene Therapy Center at Mass Eye and Ear. “The AAV-based platform provides a new approach to vaccines never used before, and outside-the-box strategies that can get more inoculations to a greater number of people regardless of where they live remain profoundly needed.”
Future study of vaccine platform and new delivery methods
The peer-reviewed findings build on preprint results published earlier this year that showed efficacy and potency at three-month tests, and the team plans to continue to collect data on the duration of response from a single-dose injection.
The team will also explore additional delivery options for the vaccine, including for needleless vaccine delivery. The temperature stability of AAVCOVID observed in the study could lend itself to easier-to-distribute formulations of the vaccine, such as in liquid drops or pills that can be shipped to far reaches of the globe commercially.
AAVCOVID researchers hope their findings can compel additional study in clinical trials.
AAVCOVID is developed through an academia-industry consortium comprised of groups within Mass Eye and Ear and Massachusetts General Hospital —both member hospitals of Mass General Brigham in Boston and the University of Pennsylvania in Philadelphia.
Dr. Vandenberghe is leading the project with co-investigators Mason Freeman, MD, who serves as director of the Translational Medicine Group of the Mass General Center for Computational and Integrative Biology and is Professor of Medicine at Harvard Medical School; and gene therapy pioneer James M. Wilson, MD, PhD, director, Gene Therapy Program at the University of Pennsylvania; Rose H. Weiss Professor and Director, Orphan Disease Center; professor in Departments of Medicine and Pediatrics, Perelman School of Medicine. Novartis Gene Therapies contributes to the consortium its unique technology, expertise and supply chain to manufacture at-scale AAVCOVID for clinical trial testing through an in-kind donation.
Funding for this project was provided by the Bill and Melinda Gates Foundation; private donations from the Mass Eye and Ear donor network; and grants from the Massachusetts Consortium for Pathogen Readiness and Mark and Lisa Schwartz, George Mason University Fast Grants, NIH R01 AI146779 and training grants (NIGMS T32 GM007753 and NIH T32 AI007245); Sponsored Research Agreements from Albamunity; the U.S. Centers for Disease Control and Prevention CK000490 and an in-kind donation of AAV manufacturing services and product by Novartis Gene Therapies.
In addition to Drs. Vandenberghe, Le Grand and Zabeleta, study authors include co-investigators Dr. Freeman at Mass General and Dr. Wilson at Penn, in addition to Wenlong Dai; Urja Bhatt; Cécile Hérate, Pauline Maisonnasse; Jessica A Chichester; Julio Sanmiguel; Reynette Estelien; Kristofer T Michalson; Cheikh Diop; Dawid Maciorowski; Nathalie Dereuddre-Bosquet; Mariangela Cavarelli; Anne-Sophie Gallouët; Thibaut Naninck; Nidhal Kahlaoui; Julien Lemaitre; Wenbin Qi; Elissa Hudspeth; Allison Cucalon; Cecilia D Dyer; M. Betina Pampena; James J. Knox; Regina C LaRocque; Richelle C Charles; Dan Li; Maya Kim; Abigail Sheridan; Nadia Storm; Rebecca I Johnson; Jared Feldman; Blake M Hauser; Vanessa Contreras; Romain Marlin; Raphaël Ho Tsong Fang; Catherine Chapon; Sylvie van der Werf; Eric Zinn; Aisling Ryan; Dione T Kobayashi; Ruchi Chauhan; Marion McGlynn; Edward T Ryan; Aaron G Schmidt; Brian Price; Anna Honko; Anthony Griffiths; Sam Yaghmour; Robert Hodge; Michael R. Betts.
About Mass Eye and Ear
Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass Eye and Ear specializes in ophthalmology (eye care) and otolaryngology–head and neck surgery (ear, nose and throat care). Mass Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 2021–2022 “Best Hospitals Survey,” U.S. News & World Report ranked Mass Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care. For more information about life-changing care and research at Mass Eye and Ear, visit our blog, Focus, and follow us on Instagram, Twitter and Facebook.
About CEA and IDMIT
The CEA is a French key player in research, development and innovation in four main areas: energy transition, digital transition, technology for the medicine of the future and defense and security.
IDMIT (CEA/Inserm/Université Paris-Saclay) is a department of the François Jacob Institute of Biology. The François Jacob Institute of Biology, based at the CEA Paris-Saclay sites in Fontenay-aux-Roses, Evry and the Hôpital Saint Louis, carry out research in 3 areas: radiobiology and radiotoxology, human health (on neurodegenerative and infectious diseases and on immuno-hematology), medical and environmental genomics. IDMIT is dedicated to preclinical and clinical research on human infectious diseases and immunology. Among its principal missions, it coordinates and operates a national research infrastructure for biology and health, providing its academic and industry partners with access to facilities and cutting-edge equipment for preclinical studies.
Cell Host & Microbe
Method of Research
Subject of Research
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
Article Publication Date
J.M.W. is a paid advisor to and holds equity in Scout Bio and Passage Bio; he holds equity in Surmount Bio; he also has sponsored research agreements with Amicus Therapeutics, Biogen, Elaaj Bio, Janssen, Moderna, Passage Bio, Regeneron, Scout Bio, Surmount Bio, and Ultragenyx, which are licensees of Penn technology. J.M.W. had a sponsored research agreement with Albamunity that funded this work. He also has a sponsored research agreement with G2 Bio. L.H.V. and J.M.W. are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments including vector and vaccine technologies herein described. L.H.V., W.D., U.B., N.Z. are named inventors on two patent applications relevant to AAVCOVID. W.Q., E.H., S.Y., and R.H. are employees of Novartis. M.W.F. is a paid consultant to 5AM Ventures and to Mitobridge/Astellas. L.H.V. is a paid advisor to Novartis, Akouos, and Affinia Therapeutics and serves on the Board of Directors of Affinia, Addgene, and Odylia Therapeutics. L.H.V. holds equity in Akouos and Affinia and receives sponsored research funding from Albamunity Inc. to which he is an unpaid consultant. M.R.B. receives consulting fees from Interius Biotherapeutics. R.C.L. is a subcontractor with the CDC Foundation and receives royalties from UpToDate.